Longbio Pharma (Suzhou) Co (HKSE:01779) Piotroski F-Score

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01779 Longbio Pharma (Suzhou) Co Ltd HKSE:01779
10 GF Score
Price HK$113.00
View Full Analysis

What is Longbio Pharma (Suzhou) Co Piotroski F-Score?

Longbio Pharma (Suzhou) Co does not have enough data to calculate Piotroski F-Score.

Longbio Pharma (Suzhou) Co  (HKSE:01779) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Longbio Pharma (Suzhou) Co Piotroski F-Score Related Terms


Longbio Pharma (Suzhou) Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Longbio Pharma (Suzhou) Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longbio Pharma (Suzhou) Co Piotroski F-Score Chart

Longbio Pharma (Suzhou) Co Annual Data
Trend Dec24 Dec25
Piotroski F-Score
0.00 0.00

Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24 Dec25
Piotroski F-Score 0.00 0.00

HKSE:01779 vs VRTX, REGN, RVMD: Piotroski F-Score Comparison

For the Biotechnology subindustry, Longbio Pharma (Suzhou) Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longbio Pharma (Suzhou) Co Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longbio Pharma (Suzhou) Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Longbio Pharma (Suzhou) Co's Piotroski F-Score falls into.


HKSE:01779
10GF Score
Longbio Pharma (Suzhou) Co Ltd HKSE:01779
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longbio Pharma (Suzhou) Co Business Description

Address No. 128 Yinhe Road, Dongnan Subdistrict, 5th Floor, Building F, Area A, Changshu City, Jiangsu Province, Suzhou, CHN
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score

Get the complete analysis for HKSE:01779

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$113.00
Price